News

Video

DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

Author(s):

Maria-Victoria Mateos, MD, PhD

DREAMM-7 (NCT04246047) is a global, randomized, open-label, phase III head-to-head trial evaluating the efficacy and safety of BVd triplet vs SoC triplet, DVd, in patients (pts) with RRMM with ≥1 prior line of therapy.

Related Videos
Joseph Maakaron, MD, assistant professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mohamad Mohty, MD, PhD, professor, hematology, Sorbonne University, head, Clinical Hematology and Cellular Therapy Department, Saint-Antoine Hospital
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study
Intracranial Efficacy of Datopotamab Deruxtecan in Patients with Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer with Actionable Genomic Alterations: Results from Tropion-Lung05
Marie Hu, MD, assistant professor, medicine, Division of Hematology, Oncology and Transplantation, the University of Minnesota Medical School
James Ignatz-Hoover, MD, PhD
Bertrand Arnulf, MD, PhD
Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: primary results from DESTINY-Breast06
Harry P. Erba, MD, PhD
Radhika Bansal, MBBS
Related Content
María-Victoria Mateos, MD, PhD
July 1st 2024

Belantamab Mafodotin–Based PFS Benefits in Difficult-to-Treat R/R Myeloma Subgroups

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Jeremy Abramson, MD, of Massachusetts General Hospital
June 27th 2024

Liso-cel Shows Improved EFS, PFS, and Durable Responses in Second-line LBCL at 3 Years

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Naresh Bumma, MD, an assistant professor in the Division of Hematology at The Ohio State University Comprehensive Cancer Center—James in Columbus
June 25th 2024

Linvoseltamab Displays Durable Efficacy in Relapsed/Refractory Multiple Myeloma

FDA
June 24th 2024

FDA Approves Crovalimab for Paroxysmal Nocturnal Hemoglobinuria